Sofia Fund participates in recently closed $8M financing round announced by existing portfolio company, Oculogica. This round of funding will support further commercial distribution of the EyeBOX at Level I, II and III trauma centers nationwide, including additional units in use with the U.S.…
Pittsburgh, PA, November 20, 2019 (GLOBE NEWSWIRE) – Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that President & CEO Kenneth I.…
The American Medical Association (AMA) has confirmed the addition of a new Category 3 CPT Code, 0X17T, Eye movement analysis test without spatial calibration, allowing clinicians to appropriately report the services related exclusively to the Oculogica EyeBOX® exam.
Read the entire press release here:
https://www.biospace.com/article/releases/oculogica-announces-new-category-3-cpt-code-created-by-american-medical-association/…
Digital Marketplace Launches REWEAR™ Collective and Style Scout Programs
Minneapolis, MN, September 26, 2019 – Kidizen, a mom-powered community that helps parents shop and sell quality secondhand kids fashion, is launching two new programs to extend the life of clothes, reducing waste.…
Portfolio company CogRX gains patent coverage in Japan and China for Elayta, Cognition’s lead drug for treatment of mild to moderate Alzheimer’s disease.
Sofia Fund portfolio company, Joylux, announces they have raised more than $9M exclusively through prominent angel investors and angel groups including the Sofia Fund and has expanded their Advisory Board by adding Dr. Michael Friedman, former FDA Commissioner.
Pittsburgh, PA, June 05, 2019 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., today announced that Anthony O. Caggiano, M.D., Ph.D. has joined the Company as chief medical officer (CMO). Cognition Therapeutics is a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative diseases and disorders caused by toxic oligomeric proteins.…
Winner of the prestigious Luis Villalobos Award, honoring ingenuity and innovation among start up companies.
Seattle, WA, April 25, 2019 — Joylux, a leading FemTech company using high-tech solutions to improve women’s intimate health, has been named the most innovative company by Angel Capital Association (ACA) members, a membership of 14,000+ accredited angel investors.…
Pittsburgh, PA, March 26, 2019 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative diseases and disorders caused by membrane trafficking dysfunction, today announced the appointment of Lisa Ricciardi to its Board of Directors.…
Joylux to be honored at the Angel Capital Association’s 2019 Summit as a top-three finalist for the prestigious Luis Villalobos Award
Seattle, WA, March 25, 2019 — Joylux, a leading FemTech company using high-tech solutions to improve vaginal health for postpartum and menopausal women, has been named one of the top three most ingenious and innovative companies funded by Angel Capital Association (ACA) members, a membership of 14,000+ accredited angel investors.…